Comparative Pharmacology
Head-to-head clinical analysis: HIVID versus ZERIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIVID versus ZERIT.
HIVID vs ZERIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIVID (zalcitabine) is a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to its active triphosphate form, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA, leading to chain termination and inhibition of HIV reverse transcriptase.
Nucleoside reverse transcriptase inhibitor (NRTI); after intracellular phosphorylation to stavudine triphosphate, it competes with natural substrate deoxythymidine triphosphate for incorporation into viral DNA, causing chain termination.
0.75 mg orally every 8 hours.
Adults and adolescents (≥13 years, ≥60 kg): 40 mg orally twice daily. Adults and adolescents (≥13 years, <60 kg): 30 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life 3.5 hours (range 2.9-4.1 h), prolonged to 8-12 h in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 1.0–1.6 hours (mean 1.2 h) in adults with normal renal function; prolonged to 3.5–8.0 hours in renal impairment (CrCl <50 mL/min) requiring dose adjustment
Renal: 75% as unchanged drug; fecal: 18% as metabolites; biliary: <5%
Renal: approximately 67% (as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal: minor (<10%)
Category C
Category C
Antiretroviral (NRTI)
Antiretroviral (NRTI)